Neumora Therapeutics (NMRA) Enterprise Value (2022 - 2026)

Neumora Therapeutics' Enterprise Value history runs 5 years deep, the most recent figure standing at -$147.1 million for Q1 2026.

• In Q1 2026, Enterprise Value fell 14.83% year-over-year to -$147.1 million; the TTM figure through Mar 2026 stood at -$147.1 million (down 14.83% YoY), while the FY2025 annual figure was -$182.5 million, up 40.66% from the prior year.
• Enterprise Value was -$147.1 million for Q1 2026 at Neumora Therapeutics, up from -$182.5 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$124.5 million in Q2 2025 to a low of -$509.6 million in Q3 2023.
• Historically, Enterprise Value has averaged -$272.9 million across 5 years, with a median of -$252.5 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Enterprise Value sank 101.8% in 2023, then jumped 69.7% in 2025.
• A 5-year view of Enterprise Value shows it stood at -$371.9 million in 2022, then dropped by 22.08% to -$454.0 million in 2023, then soared by 32.25% to -$307.6 million in 2024, then surged by 40.66% to -$182.5 million in 2025, then increased by 19.43% to -$147.1 million in 2026.
• The last three Enterprise Value figures came in at -$147.1 million (Q1 2026), -$182.5 million (Q4 2025), and -$129.1 million (Q3 2025), per Business Quant data.